Back to Search Start Over

Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease.

Authors :
Hermann, Peter
Appleby, Brian
Brandel, Jean-Philippe
Caughey, Byron
Collins, Steven
Geschwind, Michael D
Green, Alison
Haïk, Stephane
Kovacs, Gabor G
Ladogana, Anna
Llorens, Franc
Mead, Simon
Nishida, Noriyuki
Pal, Suvankar
Parchi, Piero
Pocchiari, Maurizio
Satoh, Katsuya
Zanusso, Gianluigi
Zerr, Inga
Source :
Lancet Neurology. Mar2021, Vol. 20 Issue 3, p235-246. 12p.
Publication Year :
2021

Abstract

Sporadic Creutzfeldt-Jakob disease is a fatal neurodegenerative disease caused by misfolded prion proteins (PrPSc). Effective therapeutics are currently not available and accurate diagnosis can be challenging. Clinical diagnostic criteria use a combination of characteristic neuropsychiatric symptoms, CSF proteins 14-3-3, MRI, and EEG. Supportive biomarkers, such as high CSF total tau, could aid the diagnostic process. However, discordant studies have led to controversies about the clinical value of some established surrogate biomarkers. Development and clinical application of disease-specific protein aggregation and amplification assays, such as real-time quaking induced conversion (RT-QuIC), have constituted major breakthroughs for the confident pre-mortem diagnosis of sporadic Creutzfeldt-Jakob disease. Updated criteria for the diagnosis of sporadic Creutzfeldt-Jakob disease, including application of RT-QuIC, should improve early clinical confirmation, surveillance, assessment of PrPSc seeding activity in different tissues, and trial monitoring. Moreover, emerging blood-based, prognostic, and potentially pre-symptomatic biomarker candidates are under investigation. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14744422
Volume :
20
Issue :
3
Database :
Academic Search Index
Journal :
Lancet Neurology
Publication Type :
Academic Journal
Accession number :
148852483
Full Text :
https://doi.org/10.1016/S1474-4422(20)30477-4